Terminated PHASE1 INTERVENTIONAL 2-arm NCT06039384

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Sponsor: Incyte Corporation

Conditions Advanced Solid Tumors

Interventions INCB099280 adagrasib

Updated 14 times since 2023 Last updated: Jul 30, 2025 Started: Dec 28, 2023 Primary completion: Apr 11, 2025 Completion: Jul 11, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This was a strategic business decision. There were no safety concerns contributing to this decision.

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

Other Advanced Solid Tumors trials with similar outcome

Browse all Advanced Solid Tumors trials

This PHASE1 trial investigates Advanced Solid Tumors and is currently terminated or withdrawn. Incyte Corporation leads this study, which shows 14 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

14 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1

Status: Active Not Recruiting → Terminated
Jun 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1
Dec 2024 — Jun 2025 [monthly]

Active Not Recruiting PHASE1
Sep 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 9 earlier versions

Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1
May 2024 — Jun 2024 [monthly]

Recruiting PHASE1
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE1
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation
Mirati Therapeutics Inc.

Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Candiolo, Italy , Dallas, United States , Detroit, United States , Falls Church, United States , Greeley, United States , London, United Kingdom , Los Angeles, United States , Pozuelo de Alarcón, Spain , Rozzano, Italy and 2 more locations